Recent News

• 10.09.2025 - Lexaria Bioscience Corp. Provides Strategic Update
• 09.29.2025 - Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 09.26.2025 - Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 09.19.2025 - Lexaria’s Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
• 08.27.2025 - Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
• 08.14.2025 - Lexaria’s Phase 1b GLP-1 Study Achieves Important “Last Patient Last Visit” Milestone
• 08.06.2025 - GLP-1 “Arms Race” Broadens to Include Dozens of Companies
• 07.28.2025 - Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
• 07.23.2025 - Lexaria’s DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Recent Filings

• 10.01.2025 - D Notice of Exempt Offering of Securities
• 09.29.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.29.2025 - 8-K Current report
• 09.29.2025 - EX-99.1 EX-99.1
• 09.25.2025 - 8-K Current report
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.30.2025 - 4 Statement of changes in beneficial ownership of securities